← FDA DRUG APPROVALS

FDA ANDA · ANDA206739

ASPIRIN AND DIPYRIDAMOLE

Sponsor: SANDOZ

APPLICATION
ANDA206739
TYPE
ANDA
ORIGINAL APPROVAL
2017-01-18
LATEST ACTION
2022-01-19
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

ASPIRIN AND DIPYRIDAMOLEPrescription
ASPIRIN 25MG, DIPYRIDAMOLE 200MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2022-01-19Labeling · Supplement 4 · standardAP
2020-11-10Labeling · Supplement 1 · standardAP
2020-11-10Labeling · Supplement 2 · standardAP
2017-01-18UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →